<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690118</url>
  </required_header>
  <id_info>
    <org_study_id>GERP ALS</org_study_id>
    <secondary_id>EUDRACT NUMBER 2006-005410-13</secondary_id>
    <nct_id>NCT00690118</nct_id>
  </id_info>
  <brief_title>Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Efficacy, Safety and Tolerability Study of 45 mg Pioglitazone in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      Efficacy of pioglitazone (45 mg/day) as add-on therapy to standard therapy with riluzole in
      patients with ALS compared to placebo in terms of survival (mortality defined exclusively as
      death).

      This is a prospective, multicentre, randomised, stratified, parallel-group, double-blind
      trial comparing placebo with 45 mg pioglitazone as add-on therapy to 100 mg riluzole in ALS
      in 220 enrolled patients. For entry, the El Escorial Criteria for diagnosis will be used. The
      duration of treatment will be 18 months. The primary endpoint will be subjected to a
      confirmatory analyses. Secondary variables will be incidence of tracheotomy or non-invasive
      ventilation, ALS Functional Rating Scale, Quality of life and safety variables.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The interim analysis showed no tendency in favour of the verum group. Therefore it was decided
    to stop the study prematurely.
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival in patients with ALS treated with pioglitazone compared to placebo</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of tracheotomy or non-invasive ventilation</measure>
    <time_frame>18 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>45 mg/day, 18 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>once daily, 18 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  possible, probable (clinically or laboratory) or definite ALS according to the revised
             version of the El Escorial World Federation of Neurology criteria

          -  disease duration more than 6 months and less than 3 years

          -  best-sitting FVC between 50% and 95% of predicted normal

          -  continuously treated with 100 mg riluzole daily, for at least one month

          -  onset of progression weakness within 36 months prior to study

          -  women of childbearing age be non-lactating and surgically sterile or using a highly
             effective method of birth control and have a negative pregnancy test

          -  capable of thoroughly understanding all information given and giving full informed
             consent according to GCP

        Exclusion Criteria:

          -  previous participation in another clinical study within the preceding three months

          -  tracheotomy or assisted ventilation of any type during the preceding three months

          -  gastrostomy

          -  any medical condition known to have an association with motor neuron dysfunction which
             might confound or obscure the diagnosis of ALS

          -  presence of any concomitant life-threatening disease or impairment likely to interfere
             with functional assessment

          -  confirmed hepatic insufficiency or abnormal liver function (ASAT and/or ALAT more than
             1.5 upper limit of normal)

          -  renal insufficiency (serum creatinine more than 2.26 mg/dl)

          -  evidence of major psychiatric disorder or clinically evident dementia precluding
             evaluation of symptoms

          -  known hypersensitivity to any component of the study drugs

          -  likely to be not cooperative or comply with the trial requirements (as assessed by the
             investigator), or unable to be reached in the case of an emergency

          -  other antidiabetics

          -  heart failure or heart failure in the patients history (NYHA I to IV)

          -  history of macular oedema

          -  treatment with thiazolidinediones within 3 months prior to screening

          -  known or suspected history of alcohol and/or drug abuse

          -  treatment with gemfibrozil within 3 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert C Ludolph, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, University of Ulm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, University of Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology and Center for Palliative Medicine, University of Munich</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>D-81366</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Universty of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>D-93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Deutsche Klinik für Diagnostik</name>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <zip>D-65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Rostock</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>D-18147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Goettingen</name>
      <address>
        <city>Goettingen</city>
        <state>Niedersachsen</state>
        <zip>D-37073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Medical School Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik Bergmannsheil</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Universty of Muenster</name>
      <address>
        <city>Muenster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Universty of Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhrein-Westfalen</state>
        <zip>D-53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Halle-Wittenberg</name>
      <address>
        <city>Halle/Saale</city>
        <state>Sachsen-Anhalt</state>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, TU Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Jena</name>
      <address>
        <city>Jena</city>
        <state>Thueringen</state>
        <zip>D-07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Humboldt University</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <reference>
    <citation>Schütz B, Reimann J, Dumitrescu-Ozimek L, Kappes-Horn K, Landreth GE, Schürmann B, Zimmer A, Heneka MT. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci. 2005 Aug 24;25(34):7805-12.</citation>
    <PMID>16120782</PMID>
  </reference>
  <reference>
    <citation>Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2005 Feb;191(2):331-6.</citation>
    <PMID>15649489</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <last_update_submitted>May 28, 2015</last_update_submitted>
  <last_update_submitted_qc>May 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Albert Christian Ludolph, Prof.</investigator_full_name>
    <investigator_title>Coordinating Investigator</investigator_title>
  </responsible_party>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <keyword>survival time</keyword>
  <keyword>ALS functioning Rating Scale</keyword>
  <keyword>quality of life</keyword>
  <keyword>non-invasive ventilation</keyword>
  <keyword>clinical tolerability</keyword>
  <keyword>survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

